You are here

Share:

Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer

Summary
NIH scientists have created and characterized a transgenic model that is currently an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials. The mouse model also develops prostate intraepithelial neoplasia and prostate cancer, therefore has also been used for studies of prostate cancer. The NCI seeks parties interested to utilize or further develop this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.
NIH Reference Number
E-191-2010
Product Type
Keywords
  • triple-negative breast cancer
  • prostate
  • mouse
  • murine
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

The NCI Laboratory of Cancer Biology and Genetics seeks parties interested in collaborative research to further develop this mouse model of triple-negative breast cancer (TNBC) to study cancer biology and for preclinical testing.  As a Research Tool, patent protection is not being pursued for this technology.

Basal triple-negative breast cancer (TNBC) is a common form of human breast cancer for which there are no specific, targeted therapies, unlike hormone-responsive or Her2+ breast cancers. TNBC has a much worse prognosis than hormone receptor + cancer and is disproportionately high in the African-American population. NIH scientists have created and characterized a transgenic model that is currently an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials. The mouse model also develops prostate intraepithelial neoplasia and prostate cancer, therefore has also been used for studies of prostate cancer.

Potential Commercial Applications
  • Mouse model for pre-clinical validations
Competitive Advantages
  • Shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies
Inventor(s)

Jeffrey E. Green (NCI)

Development Stage
Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number
Therapeutic Area
Updated
Wednesday, May 30, 2018